Tango Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Tango Therapeutics, Inc. (TNGX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -0.10% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-05
- Tango Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -0.10%.
- Tango Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.20%.
- Tango Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.10%, a 116.67% decline from fiscal 2021.
- Tango Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.60%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -0.10% 10-K · filed 2026-03-05 |
| 2023-12-31 | -0.20% 10-K · filed 2026-03-05 |
| 2022-12-31 | -0.10% 10-K · filed 2025-02-27 |
| 2021-12-31 | 0.60% 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |